OBJECTIVE: To assess levels of glial fibrillar acidic protein (GFAP), myelin basic protein (MBP), neurone-specific enolase (NSE) and S100B in patients with first-onset schizophrenia. METHOD: We investigated CSF and serum samples from 12 patients with first-onset schizophrenia and from 17 control subjects by ELISA (GFAP, MBP) or immunoluminometric sandwich assays (NSE, S100B). RESULTS: Patients with schizophrenia had significantly higher levels of S100B in CSF (p = 0.004; 2.73 (SD 0.80) v 1.92 (0.58) microg/l) and serum (p = 0.032; 0.09 (0.03) v 0.08 (0.02) microg/l) in comparison with those in the matched control group. No diagnosis-dependent differences of protein concentration were seen for GFAP, MBP and NSE. DISCUSSION: Our finding of increased levels of S100B in patients with schizophrenia without an indication for significant glial (GFAP, MBP) or neuronal (NSE) damage may be interpreted as indirect evidence for increased active secretion of S100B during acute psychosis.
OBJECTIVE: To assess levels of glial fibrillar acidic protein (GFAP), myelin basic protein (MBP), neurone-specific enolase (NSE) and S100B in patients with first-onset schizophrenia. METHOD: We investigated CSF and serum samples from 12 patients with first-onset schizophrenia and from 17 control subjects by ELISA (GFAP, MBP) or immunoluminometric sandwich assays (NSE, S100B). RESULTS:Patients with schizophrenia had significantly higher levels of S100B in CSF (p = 0.004; 2.73 (SD 0.80) v 1.92 (0.58) microg/l) and serum (p = 0.032; 0.09 (0.03) v 0.08 (0.02) microg/l) in comparison with those in the matched control group. No diagnosis-dependent differences of protein concentration were seen for GFAP, MBP and NSE. DISCUSSION: Our finding of increased levels of S100B in patients with schizophrenia without an indication for significant glial (GFAP, MBP) or neuronal (NSE) damage may be interpreted as indirect evidence for increased active secretion of S100B during acute psychosis.
Authors: D R Lara; C S Gama; P Belmonte-de-Abreu; L V Portela; C A Gonçalves; M Fonseca; S Hauck; D O Souza Journal: J Psychiatr Res Date: 2001 Jan-Feb Impact factor: 4.791
Authors: A Petzold; R Jenkins; H C Watt; A J E Green; E J Thompson; G Keir; N C Fox; M N Rossor Journal: Neurosci Lett Date: 2003-01-23 Impact factor: 3.046
Authors: Huiqiong Deng; Ramandeep S Kahlon; Satyajit Mohite; Pooja A Amin; Giovana Zunta-Soares; Gabriela D Colpo; Laura Stertz; Gabriel R Fries; Consuelo Walss-Bass; Jair C Soares; Olaoluwa O Okusaga Journal: Psychiatr Q Date: 2018-03
Authors: Johann Steiner; Aye Mu Myint; Kolja Schiltz; Sabine Westphal; Hans-Gert Bernstein; Martin Walter; Matthias L Schroeter; Markus J Schwarz; Bernhard Bogerts Journal: Cardiovasc Psychiatry Neurol Date: 2010-06-10
Authors: Andrea Kleindienst; Christian Schmidt; Hans Parsch; Irene Emtmann; Yu Xu; Michael Buchfelder Journal: Cardiovasc Psychiatry Neurol Date: 2010-07-08
Authors: Márcia L Chaves; Ana L Camozzato; Eduardo D Ferreira; Isabel Piazenski; Renata Kochhann; Oscar Dall'Igna; Guilherme S Mazzini; Diogo O Souza; Luis V Portela Journal: J Neuroinflammation Date: 2010-01-27 Impact factor: 8.322